Degenerative lumbar spondylolisthesis
Conditions
Interventions
RCT study: Traditional Chinese Medicine group:Oral Chinese herbal decoctions
RCT study: manual therapy group:Using manual massage therapy
RCT study: Chinese medicine combined with manual therapy group:Using oral Chinese medicine combined with massage therapy for treatment
RCT study: Western medicine group:Oral Celecoxib Capsules Combined with Waist Fixation
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University
Eligibility
Sex/Gender
All
Age
50 Years to 100 Years
Inclusion criteria
Inclusion criteria: In order to be included in this experiment, participants must: 1) Simultaneously meeting the diagnostic criteria for chronic back pain in traditional Chinese medicine and degenerative lumbar spondylolisthesis in Western medicine; 2) Age = 50 years old, male or female not limited; 3) Lower back pain VAS score = 4 points; 4) I voluntarily participate in this experiment and sign the informed consent form. 5) Lumbar spondylolisthesis is classified as Grade I and Grade II
Exclusion criteria
Exclusion criteria: Participants who fall under any of the following circumstances will be excluded from this trial: 1) Lumbar spondylolisthesis caused by congenital spinal lesions, as well as developmental dysplasia, isthmus, traumatic, and pathological lumbar spondylolisthesis; 2) Slippery caused by spinal infections, traumatic fractures, tumors, tuberculosis, and osteoporosis; 3) Patients with other serious primary diseases and complications in internal medicine, such as severe liver or kidney disease, severe heart disease or poorly controlled hypertension, diabetes, severe gastrointestinal diseases or digestive system problems; 4) Individuals who have undergone lumbar surgery or other major surgeries; 5) Patients with severe skin damage or skin diseases in the manipulation area; 6) Contraindications for manipulation: such as obvious neurological dysfunction or progressive aggravation; 7) Use traditional Chinese medicine within 4 weeks; 8) Acupuncture and moxibustion or acupotomy and other invasive Chinese medicine treatment were performed within 1 week before treatment, and local blocking treatment was performed within 3 weeks; 9) Use within 7 days prior to randomization or plan to use nonsteroidal anti-inflammatory drugs during the study period (excluding acetaminophen tablets with a daily dose not exceeding 2000mg); 10) Within 30 days of use or planned use of opioid drugs or corticosteroids during the study period (but only subjects who require inhaled corticosteroids for asthma treatment may be enrolled); 11) Patients who are allergic to or have significant drug intolerance to the drugs used in this study; 12) Patients with a history of drug abuse; 13) Patients currently participating in other clinical trials; The study suggests that there are other patients who are not suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual Analog Scale; | — |
Secondary
| Measure | Time frame |
|---|---|
| Oswestry disability index;36-item Short-Form;Efficient;the frequency of attacks and the duration of each episode;X-ray of lumbar;Lumbar spine mobility;Gait feature monitoring;Lower limb Visual Analog Scale pain score;Cost effectiveness ratio analysis; | — |
Countries
China
Contacts
Public ContactChengliang Wu
Zhejiang Chinese Medical University
Outcome results
None listed